New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

TAGRISSO™ (osimertinib) tablet, for oral use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

Facts of Tagrisso (osimertinib)

TAGRISSO™ (osimertinib) tablet, for oral use
Initial U.S. Approval: 2015
Tablets: 80 mg and 40 mg

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Tagrisso (osimertinib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Tagrisso (osimertinib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.


Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Tagrisso is?

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

TAGRISSO is a kinase inhibitor indicated for the treatment of patients with

  • metastatic epidermal growth factor receptor (EGFR) T790M mutationpositive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, who have progressed on or after EGFR TKI therapy.
  • This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

What Osimertinib is?

Osimertinib (previously known as mereletinib; trade name Tagrisso) is a medication used to treat non-small-cell lung carcinomas with specific mutations.
It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Developed by AstraZeneca, the medication was approved as a cancer treatment in 2017 by both the Food and Drug Administration and the European Commission.

Related Products